Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Outlook Therapeutics
AddedFeb 19, 2024
UpdatedJun 18, 2026
Outlook Therapeutics

Outlook Therapeutics

Public

Outlook Therapeutics: A US-based biopharmaceutical firm focusing on developing complex biosimilar therapeutics.

HQ
Cranbury, NJ, US
Founded
2011
Overview
Compare
Fundraising
Employees
Website

Outlook Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first FDA-approved ophthalmic formulation of bevacizumab. Their primary target is the treatment of wet age-related macular degeneration (AMD). The company's core mission revolves around identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics, with a particular emphasis on monoclonal antibodies in immunology and oncology.

The company has made significant strides in its development efforts, recently receiving European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD. This achievement marks a crucial milestone in Outlook Therapeutics' journey towards bringing innovative ophthalmic treatments to market, potentially impacting patient care in the field of ophthalmology.

Outlook Therapeutics - Similar Companies

Ocular Therapeutix logo

Ocular Therapeutix

ocutx.com

ONL Therapeutics logo

ONL Therapeutics

Outpost Medicine logo

Outpost Medicine

Ocumension Therapeutics logo

Ocumension Therapeutics

Visiox logo

Visiox

visioxpharma.com

Nimbus Therapeutics logo

Nimbus Therapeutics

nimbustx.com

Coherus BioSciences logo

Coherus BioSciences

coherus.com

Oculogenex logo

Oculogenex

oculogenex.com

OcuCure Therapeutics logo

OcuCure Therapeutics

Abvc Biopharma logo

Abvc Biopharma

Osprey Pharmaceuticals USA logo

Osprey Pharmaceuticals USA

ospreypharma.com

Hyperion DeFi logo

Hyperion DeFi

eyenovia.com

Iview Therapeutics logo

Iview Therapeutics

Summit Therapeutics logo

Summit Therapeutics

summittxinc.com

Oviva Therapeutics logo

Oviva Therapeutics

ovivatx.com

Outlook Therapeutics - Quick Facts

Who are Outlook Therapeutics' competitors?

Companies similar to Outlook Therapeutics include Ocular Therapeutix, ONL Therapeutics, Outpost Medicine and Ocumension Therapeutics.

When was Outlook Therapeutics founded?

Outlook Therapeutics was founded in 2011.

Where is Outlook Therapeutics' headquarters located?

Outlook Therapeutics' headquarters is located in Cranbury, NJ, US.

When was Outlook Therapeutics' last funding round?

Outlook Therapeutics' most recent funding round was for $65M (USD) in January 2024.

How much has Outlook Therapeutics raised to-date?

As of Jan 23, 2024, Outlook Therapeutics has raised a total of $335.3M (USD).

How many employees does Outlook Therapeutics have?

Outlook Therapeutics has 46 employees as of Feb 6, 2024.

Outlook Therapeutics - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biosimilars
  • Therapeutics
Tags
  • Healthcare
  • Healthtech
Unique IDs
  • ein: 383982704
  • secCik: 0001649989
  • ticker: OTLK
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2836Biological Products, Except Diagnostic Substances
  • 2800Chemicals And Allied Products
  • 2830Drugs
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 16 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325414Biological Product (except Diagnostic) Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research